Will Rucaparib be reimbursed by medical insurance?

Since Rucaparib (Rucaparib) has not yet been launched in China, it has not been included in the medical insurance coverage standards. Domestic patients have not been able to use medical insurance for reimbursement, nor can they purchase this drug through domestic channels. The specific time when it will enter the medical insurance is unclear. Rucaparib is marketed overseas to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (cancer of the lining of the abdominal organs). Rucaparib is sometimes used in these cases only if the patient's cancer has a specific genetic marker (an abnormal "BRCA" gene). Doctors testfor this gene in cancers. Rucaparib is also used to treat prostate cancer with BRCA gene abnormalities.